"Last week, we presented data from nearly 90 ccRCC patients demonstrating casdatifan’s potential best-in-class profile," said Terry Rosen, Ph.D., chief executive officer of Arcus. "Given the ...

efficacy or safety of Arcus’s investigational products, including their potential for a best-in-class profile; the expected closing of the common stock offering and the expected participation in ...